Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age… Read more
Emmaus Life Sciences Inc (EMMA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.007x
Based on the latest financial reports, Emmaus Life Sciences Inc (EMMA) has a cash flow conversion efficiency ratio of -0.007x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($409.00K) by net assets ($-59.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Emmaus Life Sciences Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Emmaus Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Emmaus Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Emmaus Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Uniinfo Telecom Services Limited
NSE:UNIINFO
|
0.029x |
|
Hestia Insight Inc
OTCQB:HSTA
|
-0.324x |
|
BOOZ ALLEN HAM-A
BE:BZ9
|
0.489x |
|
Coreo AG
F:CORE
|
-0.041x |
|
SYROS PHARMAC.NEW DL-001
F:0S90
|
N/A |
|
Giant Motorsports Inc
PINK:BZRD
|
0.085x |
|
Genomic Vision Société Anonyme
F:G09
|
0.485x |
|
CL8 Holdings Ltd
AU:CL8
|
0.158x |
Annual Cash Flow Conversion Efficiency for Emmaus Life Sciences Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Emmaus Life Sciences Inc from 1999 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-56.48 Million | $-2.29 Million | 0.040x | +28.61% |
| 2023-12-31 | $-47.76 Million | $-1.50 Million | 0.031x | -78.85% |
| 2022-12-31 | $-34.09 Million | $-5.07 Million | 0.149x | +154.54% |
| 2021-12-31 | $-21.45 Million | $-1.25 Million | 0.058x | -87.07% |
| 2020-12-31 | $-5.42 Million | $-2.45 Million | 0.452x | +10.53% |
| 2019-12-31 | $-11.05 Million | $-4.52 Million | 0.409x | +114.88% |
| 2018-12-31 | $3.29 Million | $-9.04 Million | -2.750x | -160.98% |
| 2017-12-31 | $4.55 Million | $-4.79 Million | -1.054x | -109.08% |
| 2016-12-31 | $-256.50K | $-2.98 Million | 11.612x | +2555.57% |
| 2015-12-31 | $-4.84 Million | $-2.11 Million | 0.437x | -76.45% |
| 2014-12-31 | $-1.76 Million | $-3.27 Million | 1.857x | +32.10% |
| 2013-12-31 | $-2.16 Million | $-3.04 Million | 1.406x | +598.67% |
| 2012-12-31 | $-13.07 Million | $-2.63 Million | 0.201x | -44.84% |
| 2011-12-31 | $-11.42 Million | $-4.17 Million | 0.365x | -68.77% |
| 2010-12-31 | $-4.20 Million | $-4.91 Million | 1.168x | -71.90% |
| 2009-12-31 | $-1.11 Million | $-4.61 Million | 4.156x | +219.66% |
| 2008-12-31 | $1.05 Million | $-3.66 Million | -3.473x | -528.35% |
| 2007-12-31 | $5.35 Million | $-2.96 Million | -0.553x | -237.96% |
| 2006-12-31 | $-217.12K | $-86.99K | 0.401x | +57.78% |
| 2003-12-31 | $-25.92K | $-6.58K | 0.254x | -64.84% |
| 2002-12-31 | $-15.87K | $-11.46K | 0.722x | +40.00% |
| 2001-12-31 | $-11.73K | $-6.05K | 0.516x | +193.67% |
| 2000-12-31 | $-1.47K | $808.00 | -0.551x | -- |
| 1999-12-31 | $0.00 | $-10.00K | x | -- |